Is X4 Pharmaceuticals going out of business?

X4 Pharmaceuticals, Inc (XFOR) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

X4 Pharmaceuticals, Inc (XFOR) scores 18 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 1680.15% (YoY)

Five questions, kept separate

Survival - Fragile

23-32 mo of estimated runway from 2026-06-30, based on $195M of cash and short-term investments against $86.1M of annual burn. A disclosed filing event caps this reading; Event Risk carries the detail.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Reasonable

47.1% net-cash backing support a reasonable pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Shares dilution YoY: 1680.15% (YoY)
• FCF margin: -1324.89%
• Debt / Equity: -0.77x (Net Cash)
• ROIC: -275.39%
• Filing event risk: Going-Concern Warning (-8 pts)
• Return on Assets: -31.30%
• Asset Growth Velocity: 140.63% YoY (Aggressive buildout)
• Debt Maturity Runway: 100% long-term (Long-term focused)
• Cash Runway (years): 2.27y
• Cash Burn Deceleration: -114.65% QoQ improvement (Worsening)
• Revenue growth YoY: 41.18% (YoY) - Early-Stage Surge (low base)
• Revenue per Asset Efficiency: 2.53% QoQ

Read from filings through 2026-09-09.

Price as of 2026-09-26.